The University of Houston has announced new and evolved online business programs. Photo courtesy of University of Houston

The University of Houston's C. T. Bauer College of Business announced this month that it will begin offering fully online Master of Business Administration and Bachelor of Business Administration programs in the upcoming fall semester.

The new offerings are part of the college's 2020-2025 Strategic Plan that focuses on becoming a leader in digital learning and affordable education options.

In addition to the online BBA and MBA degrees, Bauer is launching five other fully online business-minded graduate programs:

  • Online Master of Science in Business Analytics
  • Online Master of Science in Finance
  • Online Master of Science in Management & Leadership
  • Online Master of Science in Management Information Systems
  • Online Master of Science in Supply Chain Management

Over the summer, Paul Pavlou, dean of the Bauer School and Cullen Distinguished Chair Professor, told InnovationMap that enrollment in the Bauer College had increased by about 70 percent, as the school focused on accessibility and affordability amid the pandemic and record job losses.

According to Pavlou, these new degree programs will be an extension of that effort.

"Given the recent developments due to COVID-19, and the broader challenges for higher education, it has become imperative to enhance our ability to leverage technology to offer courses remotely," he says in a statement.

The seven programs will cost between 15 to 20 percent less than traditional degree programs at the university, according to UH. The new programs will charge in-state tuition for all students, regardless of residency, and online students will not pay additional fees.

"These new offerings demonstrate our dedication to providing students financially accessible programs that emphasize innovation, technology, and experiential learning," says Paula Myrick Short, senior vice president for academic affairs and provost at UH. "Student success is our top priority, and as the need for flexible instruction and course delivery increases, we will meet that need."

The Bauer School has long been touted as one of the top schools for entrepreneurship in the country. In late 2020, UH announced that it received a $13 million donation from the Cyvia and Melvyn Wolff Family Foundation to go toward Bauer's well-known programs, as part of the school's $1.2 billion "Here We Go" initiative.
Dean Paul Pavlou of Bauer College of Business at the University of Houston shares how the school quickly pivoted to online classes and services amid the COVID-19 crisis — and how he's taking that tech into future semesters. Photo courtesy of the University of Houston

University of Houston business school dean says he's seen enrollment increase amid COVID-19

HOUSTON INNOVATORS PODCAST EPISODE 31

About a month ago, the University of Houston announced it's waiving the fees for students during the summer semester. With classes across campus switching to online only in light of the pandemic and the country experiencing historic unemployment, UH made accessibility and affordability a priority.

For the C.T. Bauer College of Business, Dean Paul Pavlou realizes the opportunities that online classes bring — like the ability to serve more students.

"One advantage of online learning is it's very flexible — we aren't confined to the classroom," Pavlou says on this week's episode of the Houston Innovators Podcast. "We've opened up more sections and seats to make it easier for students to sign up."

Bauer has seen enrollment up 70 percent for the summer, and that could be for a few reasons — the waived fees, for instance. But also, with the mandates, many of students' summer plans have been canceled — like travel and internships — have freed up students' time to get ahead in their degree.

The school had just a week to turn its in-person courses into online programming, but that's not all that had to switch to virtual. Library and career services had to make changes as well.

"Career services was one of the most challenging — not because it's so difficult to move online, but because of the tight labor market," Pavlou says. "We were actually pretty close to 100 percent placement before the pandemic."

Ultimately, as he shares on the podcast, Pavlou sees some positive things coming out of this entire experience for the university. The school has been moving forward on creating online-only degree plans that will be more affordable.

"Even when we go back to the classroom eventually, we'll be able to use this technology to supplement the class and then we'll use the classroom time in a more productive fashion," says Pavlou. "In the long run, I see that this technology can help students who cannot physically come to the classroom and can actually get almost the whole experience."

And hey, students don't have to worry about traffic, parking, or sweaty walks across campus to get to class.

Stream the episode with Pavlow below or wherever you get you podcasts — just search for the "Houston Innovators Podcast."


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”